Were Craig C. Hopkinson’s Alkermes (ALKS) share sale and option exercise pre-planned?

Yes. Both the option exercise and the 9,000-share sale were carried out under a Rule 10b5-1 trading plan. The plan was adopted on March 14, 2025, providing a pre-arranged schedule for transactions independent of day-to-day market conditions.

Alkermes (NASDAQ: ALKS) EVP reports option grants, RSUs and 9,000-share sale

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson reported a mix of equity awards, option exercises, and a share sale. He exercised employee stock options for 5,000 ordinary shares at an exercise price of $19.34 per share, then sold 9,000 ordinary shares at a weighted average price of $29.7206 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on 3/14/2025. He also received a new grant of 83,037 employee stock options and a 38,568-share restricted stock unit award, both vesting in four equal annual installments starting 3/2/2027. After these transactions, he directly holds 89,389 ordinary shares of Alkermes.

Insider Trade Summary

Net Seller: 9,000 shares ($267,485)

Net Sell 5 txns

Insider Hopkinson Craig C.

Role EVP R&D, Chief Medical Officer

Sold 9,000 shs ($267K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	5,000	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	83,037	$0.00	--
Grant/Award	Restricted Stock Unit Award	38,568	$0.00	--
Exercise	Ordinary Shares	5,000	$19.34	$97K
Sale	Ordinary Shares	9,000	$29.7206	$267K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 21,356 shares (Direct); Restricted Stock Unit Award — 38,568 shares (Direct); Ordinary Shares — 98,389 shares (Direct)

Footnotes (1)

This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.29 to $30.13. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. These options are fully vested in accordance with their terms. Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 3/2/2027. Each restricted stock unit represents a contingent right to receive one ordinary share. Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/04/2026 - 08:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkinson Craig C.

(Last)

(First)

(Middle)

900 WINTER STREET

(Street)

WALTHAM

02451

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP R&D, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	03/02/2026		M⁽¹⁾		5,000	A	$19.34	98,389	D
Ordinary Shares	03/02/2026		S⁽²⁾		9,000	D	$29.7206⁽³⁾	89,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Buy)	$19.34	03/02/2026		M⁽¹⁾			5,000	⁽⁴⁾	02/22/2031	Ordinary Shares	5,000	$0	21,356	D
Employee Stock Option (Right to Buy)	$30.25	03/02/2026		A		83,037		⁽⁵⁾	03/02/2036	Ordinary Shares	83,037	$0	83,037	D
Restricted Stock Unit Award	⁽⁶⁾	03/02/2026		A		38,568		⁽⁷⁾	⁽⁷⁾	Ordinary Shares	38,568	$0	38,568	D

Explanation of Responses:

1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.29 to $30.13. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

4. These options are fully vested in accordance with their terms.

5. Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 3/2/2027.

6. Each restricted stock unit represents a contingent right to receive one ordinary share.

7. Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027.

	/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Alkermes (ALKS) executive Craig C. Hopkinson report?

Craig C. Hopkinson reported exercising 5,000 stock options, selling 9,000 ordinary shares, and receiving new equity awards. The awards include 83,037 stock options and 38,568 restricted stock units, all dated March 2, 2026, reflecting routine executive compensation activity.

How many Alkermes (ALKS) shares did Craig C. Hopkinson sell and at what price?

He sold 9,000 Alkermes ordinary shares at a weighted average price of $29.7206 per share. The trades occurred in multiple transactions between $29.29 and $30.13, executed under a pre-established Rule 10b5-1 trading plan adopted on March 14, 2025.

What new equity awards did Craig C. Hopkinson receive from Alkermes (ALKS)?

He received 83,037 employee stock options and a restricted stock unit award covering 38,568 ordinary shares. Both awards vest in four equal annual installments beginning March 2, 2027, aligning long-term incentives with his continued service at Alkermes.

How many Alkermes (ALKS) shares does Craig C. Hopkinson own after these transactions?

Following the reported transactions, Craig C. Hopkinson directly owns 89,389 Alkermes ordinary shares. This figure reflects his option exercise of 5,000 shares and subsequent sale of 9,000 shares, as disclosed in the Form 4 ownership totals.